At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 35 enrolled
Drug / intervention
Atovaquone Proguanil +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Evaluation of Weekly Dosing of Atovaquone/Proguanil (Malarone ®) for Malaria Chemoprophylaxis
U.S. Army Medical Research and Development Command·interventional·Posted Sep 25, 2009·Updated Nov 25, 2013
In Brief
A Phase 2 clinical trial evaluating Atovaquone Proguanil and Procedure - malaria challenge for Malaria. Completed, enrolled 35 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether Malarone ®, which is a drug approved to prevent malaria when taken daily, will still effectively prevent malaria if taken weekly.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalaria
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2009
First PostedSep 2009
Primary CompletionApr 2010
TodayJul 2026
First PostedSep 25, 2009
Enrollment StartSep 1, 2009
Primary CompletionApr 1, 2010
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 16.8 years ago
Interventions
Atovaquone Proguanildrug
Volunteers will receive doses of atovaquone/proguanil (Malarone) or matching sugar pills.
Procedure - malaria challengeother
2\) Procedure- Malaria Challenge- Volunteers will be exposed to bites of infectious mosquitoes with the intention of causing malaria infection. Volunteers infected with malaria will undergo approved treatments for malaria.